BerGenBio Announces First Patient Dosed in BGB324 AML Trial

Oslo Cancer Cluster member BerGenBio AS announces first patient dosed in its multi-centre Phase 1b trial (BGBC003) of BGB324, a selective inhibitor of Axl, in patients with acute myeloid leukaemia (AML) at Haukeland University Hospital in Bergen, Norway. The two part Phase 1b trial will primarily investigate the safety and tolerability of BGB324 when administered […]

Targovax AS has reached primary endpoint in ongoing phase I/II trial

Oslo Cancer Cluster member Targovax AS has reached an important milestone in the ongoing clinical trial investigating its cancer vaccine TG01 for treatment of operable pancreatic cancer. Targovax announces that the primary endpoint for the ongoing phase I/II clinical trial CT TG01-01, regarding immune response and side effects, is already reached. Recruitment of patients for […]

Innovation Camp on personalized cancer medicine

Almost 350 students at Oslo and Akershus University College of Applied Sciences was engaged in last weeks Innovation Camp where they were asked to come up with original ideas on how to communicate personalized cancer medicine. Photo: Cicilie S. Andersen/Khrono   Last week Oslo Cancer Cluster, Young Entrepreneurship Oslo, Oslo and Akershus University College of […]

4 new members in Oslo Cancer Cluster

Oslo Cancer Cluster would like to welcome our four new members on board: DNB Bank, Oslo and Akershus University College: Faculty of Health Sciences, Scandinavian Development Services and Prostataklinikken. Read more about them here:   DNB Bank ASA “DNB is a leading international bank within certain industries playing a significant role in financing and facilitating […]

Call in Immuno-Oncology: 9 applications received

By deadline November 15, Oslo Cancer Cluster received 9 applications for collaborative innovation projects addressing our Immuno-Oncology call on MNOK 1, 2. The applications are now being evaluated and the winners will be announced on Oslo Cancer Cluster`s Christmas Meeting, December 1st. – We are very pleased about the significant interest and very positive feedback […]